Cargando…

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dora, David, Ligeti, Balazs, Kovacs, Tamas, Revisnyei, Peter, Galffy, Gabriella, Dulka, Edit, Krizsán, Dániel, Kalcsevszki, Regina, Megyesfalvi, Zsolt, Dome, Balazs, Weiss, Glen J., Lohinai, Zoltan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184596/ https://www.ncbi.nlm.nih.gov/pubmed/37197440 http://dx.doi.org/10.1080/2162402X.2023.2204746

Ejemplares similares

Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer
por: Dora, David, et al.
Publicado: (2023)

Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2019)

Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients
por: Marfil-Sánchez, Andrea, et al.
Publicado: (2021)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients
por: Ni, Yueqiong, et al.
Publicado: (2021)

Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions
por: Seelbinder, Bastian, et al.
Publicado: (2023)

Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer
por: Lohinai, Zoltan, et al.
Publicado: (2019)

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2016)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer
por: Dora, David, et al.
Publicado: (2021)

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
por: Dora, David, et al.
Publicado: (2020)

HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
por: Hegedűs, Luca, et al.
Publicado: (2020)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019)

Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor
por: Radeczky, Peter, et al.
Publicado: (2021)

Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients
por: Rojko, Livia, et al.
Publicado: (2020)

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
por: Gieszer, Balazs, et al.
Publicado: (2021)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming
por: Gyukity-Sebestyén, Edina, et al.
Publicado: (2019)

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
por: Menyhárt, Otília, et al.
Publicado: (2019)

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
por: Lang, C., et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
por: Szántó, Kata Judit, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against Streptococcus suis in Pigs
por: Somogyi, Zoltán, et al.
Publicado: (2022)

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
por: Cimas, Francisco J., et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_odttuvdmdd9e1fn9n6dv9gee5f